Rock Springs Capital Management LP Has $2.31 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Rock Springs Capital Management LP decreased its position in Edwards Lifesciences Corporation (NYSE:EW) by 65.0% during the first quarter, HoldingsChannel reports. The firm owned 28,900 shares of the medical research company’s stock after selling 53,600 shares during the quarter. Rock Springs Capital Management LP’s holdings in Edwards Lifesciences were worth $2,314,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Hanson & Doremus Investment Management bought a new stake in shares of Edwards Lifesciences during the 1st quarter worth $25,000. JPL Wealth Management LLC bought a new position in Edwards Lifesciences in the 3rd quarter worth $25,000. MV Capital Management Inc. bought a new position in Edwards Lifesciences in the 4th quarter worth $26,000. RMG Wealth Management LLC bought a new position in Edwards Lifesciences in the 1st quarter worth $26,000. Finally, Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences during the 4th quarter worth $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Edwards Lifesciences

In other Edwards Lifesciences news, SVP Andrew M. Dahl sold 568 shares of the company’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the transaction, the senior vice president owned 15,334 shares of the company’s stock, valued at $1,319,950.72. This represents a 3.57% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 1,019 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $83.01, for a total value of $84,587.19. Following the completion of the sale, the vice president owned 33,934 shares of the company’s stock, valued at $2,816,861.34. This represents a 2.92% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 45,577 shares of company stock valued at $3,855,527 in the last quarter. Corporate insiders own 0.31% of the company’s stock.

Edwards Lifesciences Stock Performance

NYSE EW opened at $83.21 on Tuesday. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.42 and a quick ratio of 3.63. The firm has a market capitalization of $47.91 billion, a price-to-earnings ratio of 47.82, a P/E/G ratio of 2.07 and a beta of 0.86. The company’s fifty day moving average is $87.74 and its two-hundred day moving average is $83.86. Edwards Lifesciences Corporation has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.74 by $0.04. The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.85%. The business’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.67 EPS. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on EW. Barclays restated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. BTIG Research boosted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research report on Tuesday, June 30th. Canaccord Genuity Group set a $85.00 target price on Edwards Lifesciences and gave the company a “hold” rating in a research note on Friday, April 24th. Piper Sandler reaffirmed an “overweight” rating and issued a $101.00 target price (up from $100.00) on shares of Edwards Lifesciences in a report on Friday. Finally, Wolfe Research raised Edwards Lifesciences from a “peer perform” rating to an “outperform” rating and set a $92.00 target price on the stock in a report on Wednesday, April 1st. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.55.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.